Johnson & Johnson announced that the FDA has issued traditional approval for SIRTURO® (bedaquiline) as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.